KRYS
Krystal Biotech, Inc.
NASDAQ · USHealthcareBiotechnology
$339.22-4.41%
Price as of Jul 20, 2026
KRYS profitability
Krystal Biotech, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 92.8%
- EBITDA margin
- 48.1%
- EBIT margin
- 42.8%
- Net margin
- 53.9%
- Free cash flow margin
- 56.9%
Returns
- Return on equity
- 17.6%
- Return on assets
- 16.1%
- Return on invested capital
- 13.9%
- Asset turnover
- 0.31x
Cash efficiency
- Cash from operations
- $250.3M
- Cash per share
- $28
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.